Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 3
Submit an article Journal homepage
180
Views
11
CrossRef citations to date
0
Altmetric
Reviews

A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A

James A McSwiggen Director of Biochemistry & Bioinformatics Nastech Pharmaceutical Company, Inc., 3830 Monte Villa Parkway, Bothell, WA 98021-7266, USA +1 425 415 3045; +1 425 415 3073; [email protected]
&
Shaguna Seth Senior Research Scientist Pharmacology & Toxicology, Nastech Pharmaceutical Company, Inc., 3830 Monte Villa Parkway, Bothell, WA 98021-7266, USA
Pages 299-313 | Published online: 25 Feb 2008

Bibliography

  • Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emer Infect Dis 2006;12(1):15-22
  • WHO. Avian Influenza: assessing the pandemic threat; 2005
  • Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emer Infect Dis 1999;5(5):659-71
  • Hoeprich PD, Jordan MC. Infectious Diseases: A Modern Treatise of Infectious Processes. JB Lippincott Company, Philadelphia; 1989. p. 1527
  • Zeitlin GA, Maslow MJ. Avian influenza. Curr Allergy Asthma Rep 2006;6(2):163-70
  • Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006;13(4):644-70
  • Palese P, Shaw ML. Orthomyxoviridae: The Viruses and Their Replication. In: Fields Virology. Knipe DM, Howley PM, editors. Lippincott Williams & Wilkins, Philadelphia, PA 2007 p. 1647-89
  • Huang TS, Palese P, Krystal M. Determination of influenza virus proteins required for genome replication. J Virol 1990;64(11):5669-73
  • Kimura N, Nishida M, Nagata K, et al. Transcription of a recombinant influenza virus RNA in cells that can express the influenza virus RNA polymerase and nucleoprotein genes. J Gen Virol 1992;73(Pt 6):1321-8
  • Mena I, De La Luna S, Albo C, et al. Synthesis of biologically active influenza virus core proteins using a vaccinia virus-T7 RNA polymerase expression system. J Gen Virol 1994;75(Pt 8):2109-14
  • Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004;78(22):12665-7
  • Palese P, Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976;33(1):159-63
  • Connor RJ, Kawaoka Y, Webster RG, Paulson JC. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 1994;205(1):17-23
  • Martin K, Helenius A. Transport of incoming influenza virus nucleocapsids into the nucleus. J Virol 1991;65(1):232-44
  • Mullin AE, Dalton RM, Amorim MJ, Elton D, Digard P. Increased amounts of the influenza virus nucleoprotein do not promote higher levels of viral genome replication. J Gen Virol 2004;85(Pt 12):3689-98
  • Mikulasova A, Vareckova E, Fodor E. Transcription and replication of the influenza a virus genome. Acta Virol 2000;44(5):273-82
  • Hay AJ, Lomniczi B, Bellamy AR, Skehel JJ. Transcription of the influenza virus genome. Virology 1977;83(2):337-55
  • Cros JF, Palese P. Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses. Virus Res 2003;95(1-2):3-12
  • Veit M, Schmidt MF. Timing of palmitoylation of influenza virus hemagglutinin. FEBS Lett 1993;336(2):243-7
  • Doms RW, Lamb RA, Rose JK, Helenius A. Folding and assembly of viral membrane proteins. Virology 1993;193(2):545-62
  • Steinhauer DA, Wharton SA, Wiley DC, Skehel JJ. Deacylation of the hemagglutinin of influenza A/Aichi/2/68 has no effect on membrane fusion properties. Virology 1991;184(1):445-8
  • Sugrue RJ, Belshe RB, Hay AJ. Palmitoylation of the influenza A virus M2 protein. Virology 1990;179(1):51-6
  • Boulan ER, Sabatini DD. Asymmetric budding of viruses in epithelial monlayers: a model system for study of epithelial polarity. Proc Natl Acad Sci USA 1978;75(10):5071-5
  • Schmitt AP, Lamb RA. Influenza virus assembly and budding at the viral budozone. Adv Virus Res 2005;64:383-416
  • Nayak DP, Hui EK, Barman S. Assembly and budding of influenza virus. Virus Res 2004;106(2):147-65
  • Elleman CJ, Barclay WS. The M1 matrix protein controls the filamentous phenotype of influenza A virus. Virology 2004;321(1):144-53
  • Bourmakina SV, Garcia-Sastre A. Reverse genetics studies on the filamentous morphology of influenza A virus. J Gen Virol 2003;84(Pt 3):517-27
  • Roberts PC, Lamb RA, Compans RW. The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation. Virology 1998;240(1):127-37
  • Orson FM, Kinsey BM, Densmore CL, et al. Protection against influenza infection by cytokine-enhanced aerosol genetic immunization. J Gene Med 2006;8(4):488-97
  • Luscher-Mattli M. Influenza chemotherapy: a review of the present state of art and of new drugs in development. Arch Virol 2000;145(11):2233-48
  • De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev 2006;5(12):1015-25
  • Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996;70(3):1818-27
  • Baigent SJ, Bethell RC, McCauley JW. Genetic analysis reveals that both haemagglutinin and neuraminidase determine the sensitivity of naturally occurring avian influenza viruses to zanamivir in vitro. Virology 1999;263(2):323-38
  • Monto AS. The role of antivirals in the control of influenza. Vaccine 2003;21(16):1796-800
  • Colman PM. A novel approach to antiviral therapy for influenza. J Antimicrob Chemother 1999;44(Suppl B):17-22
  • Colman PM. Zanamivir: an influenza virus neuraminidase inhibitor. Expert Rev Anti Infect Ther 2005;3(2):191-9
  • Tompkins SM, Lo C-Y, Tumpey TM, Epstein SL. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA 2004;101(23):8682-6
  • Ge Q, Filip L, Bai A, et al. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004;101(23):8676-81
  • Napoli C, Lemieux C, Jorgensen R. Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. Plant Cell 1990;2(4):279-89
  • Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391(6669):806-11
  • Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15(2):188-200
  • Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
  • Sontheimer EJ. Assembly and function of RNA silencing complexes. Nat Rev Mol Cell Biol 2005;6(2):127-38
  • Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 2005;15(3):331-41
  • Mello CC, Conte D. Revealing the world of RNA interference. Nature 2004;431(7006):338-42
  • Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004;431(7006):343-9
  • Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431(7006):371-8
  • Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296(5567):550-3
  • Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16(8):948-58
  • Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002;26(2):199-213
  • Kim D-H, Behlke MA, Rose SD, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotech 2005;23(2):222-6
  • Rose SD, Kim DH, Amarzguioui M, et al. Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res 2005;33(13):4140-56
  • Ui-Tei K, Naito Y, Saigo K. Essential notes regarding the design of functional siRNAs for efficient mammalian RNAi. J Biomed Biotech 2006;2006(4):65052
  • Pei Y, Tuschl T. On the art of identifying effective and specific siRNAs. Nat Methods 2006;3(9):670-6
  • Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003;115(2):209-16
  • Reynolds A, Leake D, Boese Q, et al. Rational siRNA design for RNA interference. Nat Biotech 2004;22(3):326-30
  • Katoh T, Suzuki T. Specific residues at every third position of siRNA shape its efficient RNAi activity. Nucleic Acids Res 2007;35, e27
  • Ladunga I. More complete gene silencing by fewer siRNAs: transparent optimized design and biophysical signature. Nucleic Acids Res 2007;35(2):433-40
  • Ge Q, Eisen HN, Chen J. Use of siRNAs to prevent and treat influenza virus infection. Virus Res 2004;102(1):37-42
  • Naito Y, Ui-Tei K, Nishikawa T, Takebe Y, Saigo K. siVirus: web-based antiviral siRNA design software for highly divergent viral sequences. Nucleic Acids Res 2006;34(Web Server Issue):W448-50
  • Du Q, Thonberg H, Wang J, Wahlestedt C, Liang Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res 2005;33(5):1671-77. Erratum in: Nucleic Acids Res 2005;33(11):3698
  • Reynolds A, Anderson EM, Vermeulen A, et al. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 2006;12(6):988-93
  • Chen J, Ge Q, Eisen HN. RNA interference-mediated therapeutics for influenza viruses. US PTO (USA). 2006: US Patent Apll. No. 11/102,097
  • Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003;17(4):438-42
  • Saxena S, Jonsson ZO, Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003;278(45):44312-9
  • Birmingham A, Anderson EM, Reynolds A, et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006;3(3):199-204
  • Berezikov E, Thuemmler F, Van Laake LW, et al. Diversity of microRNAs in human and chimpanzee brain. Nat Genet 2006;38(12):1375-7
  • Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120(1):15-20
  • Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003;9(9):1034-48
  • Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003;31(11):2705-16
  • Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 2003;31(2):589-95
  • Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 2005;123(4):607-20
  • Quay SC, Johnson PH. RNAi Therapeutics: The Future of Medicine. Pharma 2007;18-21
  • Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotech 2006;2006(4):71659
  • Li W, Szoka FC Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007;24(3):438-49
  • Oliveira S, Storm G, Schiffelers RM. Targeted delivery of siRNA. J Biomed Biotech 2006;2006(4):63675
  • Templeton NS, Lasic DD, Frederik PM, et al. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotech 1997;15(7):647-52
  • Ren T, Song YK, Zhang G, Liu D. Structural basis of DOTMA for its high intravenous transfection activity in mouse. Gene Ther 2000;7(9):764-8
  • Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 2004;43(42):13348-56
  • Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003;42(6):463-78
  • Oupicky D, Ogris M, Howard KA, et al. Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther 2002;5(4):463-72
  • Kinsey BM, Densmore CL, Orson FM. Non-viral gene delivery to the lungs. Curr Gene Ther 2005;5(2):181-94
  • Kichler A, Chillon M, Leborgne C, Danos O, Frisch B. Intranasal gene delivery with a polyethylenimine-PEG conjugate. J Control Rel 2002;81(3):379-88
  • Thomas M, Lu JJ, Ge Q, et al. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci USA 2005;102(16):5679-84
  • Lewis DL, Wolff JA. Systemic siRNA delivery via hydrodynamic intravascular injection. Adv Drug Deliv Rev 2007;59(2-3):115-23
  • Zhou H, Jin M, Yu Z, et al. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral Res 2007;76(2):186-93
  • Gao Y, Sun L, Dong J, et al. Rapid identification of small interfering RNA that can effectively inhibit the replication of multiple influenza B virus strains. Antiviral Ther 2006;11(4):431-8
  • Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441(7092):537-41
  • John M, Constien R, Akinc A, et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature (London, UK) 2007;449(7163):745-7
  • Driskell RA, Engelhardt JF. Current status of gene therapy for inherited lung diseases. Ann Rev Physiol 2003;65:585-612
  • Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006;14(4):476-84
  • Koping-Hoggard M, Mel'nikova YS, Varum KM, Lindman B, Artursson P. Relationship between the physical shape and the efficiency of oligomeric chitosan as a gene delivery system in vitro and in vivo. J Gene Med 2003;5(2):130-41
  • Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J Virol 1986;59(2):377-83
  • Berkhout B. Proposed alternatives for the use of anti-HIV drugs. Drug Resist Update 1999;2(1):69-70
  • Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003;77(21):11531-5
  • Das AT, Brummelkamp TR, Westerhout EM, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004;78(5):2601-5
  • Gitlin L, Stone JK, Andino R. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J Virol 2005;79(2):1027-35
  • Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 2005;33(2):796-804
  • Wilson JA, Richardson CD. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 2005;79(11):7050-8
  • De Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Medhods 2006;12(10):1203-7
  • Ge Q, McManus MT, Nguyen T, et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 2003;100(5):2718-23

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.